Trials / Terminated
TerminatedNCT00998582
Artery Elasticity After Switch From Epzicom to Truvada
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Hennepin Healthcare Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Recent research as suggested that use of the HIV medication abacavir (Ziagen, or co-formulated with lamivudine as Epzicom) may increase risk for heart disease, though findings from multiple studies have been inconsistent. This pilot study will examine vascular function, a marker of heart disease risk, among patients taking abacavir as part of their HIV medications and are then randomized to: 1) switch to tenofovir, another HIV medication, or 2) continue to take abacavir.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenofovir disoproxil | Participants taking an abacavir-based HIV treatment regimen will be randomized to switch to a tenofovir-based regimen or continue taking abacavir. |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2011-06-01
- Completion
- 2011-12-01
- First posted
- 2009-10-20
- Last updated
- 2012-10-08
- Results posted
- 2012-03-23
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00998582. Inclusion in this directory is not an endorsement.